ScholarIQanswers from OpenAlex & ORCID
Ofri Mosenzon
ResearcherPublications, citations & collaboration network
Ofri Mosenzon is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ofri Mosenzon have?
ScholarIQindexed works
Ofri Mosenzon has 268 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ofri Mosenzon have?
ScholarIQcitation count
Ofri Mosenzon has 27,236 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ofri Mosenzon?
ScholarIQh-index
Ofri Mosenzon has an h-index of 56 in OpenAlex.
What is the i10-index of Ofri Mosenzon?
ScholarIQi10-index
Ofri Mosenzon has an i10-index of 118 in OpenAlex.
What is the ORCID of Ofri Mosenzon?
ScholarIQorcid
The ORCID for Ofri Mosenzon is on the source record.
What is the OpenAlex record for Ofri Mosenzon?
ScholarIQopenalex
The OpenAlex for Ofri Mosenzon is on the source record.
What are the most-cited papers on Ofri Mosenzon?
ScholarIQmost cited works
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, Ofri Mosenzon, Eri Kato, Avivit Cahn, Michael G. Silverman, Thomas A. Zelniker, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Christian T. Ruff, Ingrid Gause‐Nilsson, Martin Fredriksson, Peter A. Johansson, Anna-Maria Langkilde, Marc S. Sabatine
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, Philippe Gabríel Steg, Jaime A. Davidson, Boaz Hirshberg, Peter Öhman, Robert Frederich, Stephen D. Wiviott, Elaine Hoffman, Matthew A. Cavender, Jacob A. Udell, Nihar R. Desai, Ofri Mosenzon, Darren K. McGuire, Kausik K. Ray, Lawrence A. Leiter, Itamar Raz
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker, Stephen D. Wiviott, Itamar Raz, KyungAh Im, Erica L. Goodrich, Marc P. Bonaca, Ofri Mosenzon, Eri Kato, Avivit Cahn, Remo H.M. Furtado, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Marc S. Sabatine
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G. Eliaschewitz, Denise Reis Franco, Ole Kleist Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D. Pedersen, Cees J. Tack, Mette S. Thomsen, Tina Vilsbøll, Mark Warren, Stephen C. Bain
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O’Neil, Andreas L. Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D. Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie H. Jepsen, Maria Kabisch, John Wilding